This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by EASTMAN, R. C. Articles by KAHN, C. R. Search for Related Content PubMed PubMed Citation Articles by EASTMAN, R. C. Articles by KAHN, C. R.

Adriamycin Therapy for Advanced Insulinoma

^* Diabetes Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health Bethesda, Maryland
^** Medicine Branch, National Cancer Institute, National Institutes of Health Bethesda, Maryland
Laboratory of Kidney and Electrolyte Metabolism, National Heart and Lung Institute, National Institutes of Health Bethesda, Maryland

Reprint requests to: Dr. Richard C. Eastman, Diabetes Branch, NIAMDD Building 10, Room 8S-243, National Institutes of Health, Bethesda, Maryland 20014.

Two patients with advanced metastatic insulinoma are presented. Both failed to respond to streptozotocin and were refractory to other forms of chemotherapy. Therapy with adriamycin (Patient #1) and adriamycin plus 5-fluorouracil (Patient #2) led to significant decreases in insulin levels or measurable disease and both patients had clinical remissions lasting 5 to 7 months. Adriamycin may be effective in patients with advanced insulinoma unresponsive to conventional chemotherapy.

Received April 7, 1976.